Schlumberger Has Been Quietly Bottoming Since August - Time to Go Long
Let's check the charts of SLB to see if all that bearish news has been discounted.
2 Candidates That Could Be the Next Biotech Rockets
Omeros Corp. and EyePoint Pharmaceuticals each have promising treatments that could send their shares skyward.
Looking at Semis, The What Ifs: Brexit, China, USMCA with the UK: Market Recon
The tech sector has been the victim of the recent "on again, off again" rotation. That may really just mean that the group has been victimized by its own success.
Mr. Market Will Consolidate Gains as Earnings Roll In
Small-caps have outperformed, which helped to produce improved breadth and better stock picking, and the action is no longer being driven by trade headlines.
This Falling Knife Looks Like a Sharp Investment
Sabre made heavy investments this year that crimped net profit margins, but that should pay off handsomely starting in 2020.
Shorting the Dow at 27,000 May Not Be So Crazy
After seeing the idea raised -- and derided -- I found that the Dow has been over 27,000 twice this year and each time it did this....
Stocks Back in Focus, as China Trade News Shoved Aside
Without danger of major macro news and with earnings landing, investors focus on merits of individual stocks once again.
Jim Cramer: Here's How You Get a Not as Bad as Feared Quarter
I have the answer behind the conundrum that forces stocks up that should be going lower.
If Intuitive Surgical Is Going to Move, It Will Be Immediately Post-Earnings
As the robotics sector of medicine begins to mature, ISRG finds itself as one of the old guard.
The S&P 500 Will Soon Face Fierce Resistance - Technical AND Political
Biden's proposed doubling of the capital gains tax rate and the seemingly anti-business stance of his opponents are likely to drag the market down.